Abstract: The present invention relates to conjugates of formula (I) having colloidal stability in a medium, wherein NP is a gold, silver or platinum nanoparticle; L is a linker selected from the group consisting of formula (II), formula (III), and a stereoisomer of any of the formulas (II) and (III), which is attached to the nanoparticle NP through sulfur atoms; wherein the meanings of X, n, p, Y and s are further specified in the description; and A is a platinum (II) biradical selected from the group consisting of formula (IV), formula (V) and formula (VI) including any of the stereoisomers of all of them, wherein the biradical is optionally in the form of a salt and is attached to the linker L through the single bonded oxygen atoms of the carboxyl groups. It also relates to a process for the preparation of the conjugates of formula (I) and to pharmaceutical compositions containing them. The conjugates of the invention are used for the treatment of cancer.

Abstract: The invention relates to acrylic hydrogels with pendant cyclodextrins, the preparation and application thereof as release systems and components of contact lenses. The method for obtaining acrylic hydrogels with pendant cyclodextrins is characterized in that the hydrogels are formed by a polymer lattice obtained by polymerization of mono- and bifunctional acrylic or methacrylic monomers and monomers having glycidyl groups in their structure, to which cyclodextrin units are covalently bound once formed; and the use and applications of the compositions in the preparation of contact lenses with the capacity for incorporating drugs, active substances or demulcents useful in the treatment of pathological or physiological conditions, in the production of topical, transdermal or transmucosal release systems for medicinal products or active substances, and in the preparation of cosmetics.

Abstract: The present invention relates to nanosystems comprising metal atomic quantum clusters (AQCs) of at least two different sizes encapsulated in a cavity with an inner diameter less than or equal to 10 nm for the use thereof as luminescent nanosystems, particularly for the use thereof as fluorescent nanosystems; as well as the method for obtaining and detecting them. The invention also relates to the use of said luminescent nanosystems as a fluorescent probe, biomarker or contrasting agent.

Abstract: The present invention relates to a new method for preparing anisotropic metal nanoparticles with high aspect ratios and different types of structures by means of catalysis by Atomic Quantum Clusters (AQCs).

Abstract: An apparatus for general powering computation is disclosed. The apparatus is capable of computing a powering function of a floating-point number with an unrestricted exponent. The unrestricted exponent can be a fixed-point or a floating-point exponent. Additionally, the unrestricted exponent can be an inverse of a number in order to enable for q-th root computation using the same hardware processor and architecture.

Abstract: The invention relates to a system for administering active ingredients, including nanocapsules comprising an oil, a cationic surfactant and a polymer selected from the group consisting of polyglutamic acid (PGA), polyglutamic-polyethyleneglycol acid (PGA-PEG), hyaluronic acid (HA) and polyasparagine (PAsn) or a combination of same and, optionally, an active ingredient, with the condition that when the polymer includes polyglutamic acid or polyglutamic-polyethyleneglycol acid (PGA-PEG) the active ingredient is not a didemnin or a tamandarin. The invention also relates to methods for obtaining said nanocapsule system, the pharmaceutical compositions thereof and the use of same in medicine.

Abstract: Use of bacterial cells of the genus Tenacibaculum, from the crude cellular extract or from its cultivation supernatants, capable of degrading N-acyl homoserine lactones, for quorum quenching, for treatment of infectious bacterial illnesses or to inhibit formation of biofilms.

Abstract: The invention relates to a method for the preparation of nanoparticles in ionic liquids. Specifically, the invention relates to a simple, quick and effective method for the preparation of dispersions of nanoparticles (nanofluids) in an ionic liquid.

Abstract: Floating device for harnessing swell energy by lateral overflow, said device being formed by hulls which converge in plan view and have a variable freeboard between which the waves propagate. The convergence produces a gradual increase in the height of the wave as it propagates between the hulls, which, together with the reduction in the freeboard from a particular section of said hulls, gives rise to the lateral overflow of the mass of water of the crest over their rails, which is collected in tanks which are at different heights (in accordance with the reduction in the freeboard) and are connected to the corresponding turbines. The angle of convergence between the hulls can be varied in order to be adapted to the sea state. The harnessing system is supplemented with a connecting closure ramp between the sterns of the hulls in order to collect the water which has previously not managed to overflow the structure.

Abstract: The invention describes for first time the activity of poloxamines as inducers in the differentiation of mesenchymal or progenitor cells. In particular, the invention demonstrates that poloxamines have an osteogenic ability. The invention relates to the use of one or more poloxamines or a pharmaceutical composition comprising same for the preparation of a drug for treting patients with bone defects in general. The invention also relates to a method for inducing the differentiation of mesenchymal or progenitor cells into osteoblasts by bringing said cells into contact with a sterilised aqueous dispersion or solution of one or more poloxamines.

Abstract: The present invention relates to hydroxyapatite doped with Fe2+ ions and Fe3+ ions which partially substitute the calcium ions in the crystal lattice. The hydroxyapatite is characterized by an intrinsic magnetism of 0.05 to 8 emu/g, measured by applying a magnetic field of 34 Oe, due to the presence of magnetic nano-domains in the crystal lattice of HA, given the limited amount of magnetic secondary phases present, less than about 3% by volume. The intrinsically magnetic hydroxyapatite can be loaded with biological substances selected in the group consisting of proteins, genes, stem cells, growth factors, vascularization factors, active substances and drugs, under the control of an external magnetic field, as a carrier and release agent for biological substances or drugs, as a contrast agent in diagnostics or for bone or osteocartilage regeneration.

Abstract: The invention relates to the use of oxaloacetate in the treatment of ischaemia. The invention provides quantities that are therapeutically effective for the treatment of disorders associated with high levels of glutamate in brain tissue, such as, for example, cerebral ischaemia. In addition, the compositions of the invention are suitable for bolus-type delivery.

Abstract: Aqueous pharmaceutical system for the administration of drugs to the nails. The invention relates to a topical preparation for treating diseases of the toenails and/or hands nails, based on a thermosensitive aqueous gel that at room temperature behaves as a dissolution and after application of nails, forming a hydrated layer, film or hydrogel from which release the active ingredients. The composition of the gel contains mostly water, a gel-forming polymer sensitive to changes in temperature, solubilizing agents and enhancers of absorption and/or penetration of the drug in nails.

Abstract: The present invention relates to a new method for preparing anisotropic metal nanoparticles with high aspect ratios and different types of structures by means of catalysis by Atomic Quantum Clusters (AQCs).

Abstract: Method for the isolation and purification of nTreg cells from a biological sample, preferably from an individual having an inflammatory or autoimmune disease. Furthermore, the invention additionally relates to a kit for the isolation or purification of nTreg cells from a biological sample.

Abstract: The present invention is in the field of biomedicine pharmaceutical chemistry. Specifically, it refers to the use of yessotoxin, its derivatives and analogues, for the preparation of a medicinal drug for the prevention and/or treatment of neurodegenerative diseases related to abnormal levels of Tau and ?-amyloid proteins such as, for example, Alzheimer's disease.

Abstract: Disclosed embodiments include a method for retinal image analysis implemented in a medical system with one or more processors comprising the method steps of: (a) locating an optical disk on the retinal images and establishing a plurality of circumferences centered at the disk; (b) detecting a plurality of vessels within a region defined by said circumferences' radii using a crease-based algorithm; (c) extracting a plurality of vessel segments based on a deformable models (snakes) algorithm; and d) automatically classifying the vessels and computing clinical parameters.

Abstract: Disclosed embodiments include a method for retinal image analysis implemented in a medical system with one or more processors comprising the method steps of: (a) locating an optical disk on the retinal images and establishing a plurality of circumferences centered at the disk; (b) detecting a plurality of vessels within a region defined by said circumferences' radii using a crease-based algorithm; (c) extracting a plurality of vessel segments based on a deformable models (snakes) algorithm; (d) measuring a plurality of vessel calibers; (e) classifying each vessel as a vein and an artery; and (f) computing an arteriolar-to-venular ratio.

Abstract: The invention relates to conductive inks obtained by combining AQCs and metal nanoparticles. Atomic quantum clusters (AQCs), which melt at temperatures of less than 150° C., are used as low-temperature “flux” for the formulation of conductive inks. The combination of AQCs with bimodal and trimodal mixtures of nanoparticles of various sizes guarantees the elimination of free volumes in the final sintering of the nanoparticles in order to achieve electronic structures with very low resistivity (close to that of the bulk material) with low-temperature thermal treatments (<150° C.

Abstract: The present invention relates to the use of a compound with the following chemical structure: for the preparation of a medicament, preferably designed for the prevention or treatment of pathological processes related to the tau and ?-amyloid proteins. Preferably, the compound used is gambierol.